Citation Report
List of articles citing

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

DOI: 10.1016/j.cell.2016.01.011
Cell, 2016, 164, 770-9.

Source: https://exaly.com/paper-pdf/65338367/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
659	An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics.		
658	Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. **2016**, 14, 288		71
657	Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. **2016**, 113, 8133-8		17
656	Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases. **2016**, 8, 402-22		19
655	Chimeric antigen receptors: driving immunology towards synthetic biology. **2016**, 41, 68-76		54
654	Bioelectronic Interface Connecting Reversible Logic Gates Based on Enzyme and DNA Reactions. **2016**, 17, 2247-55		32
653	Prospects for chimeric antigen receptor (CAR) T cells: A potential game changer for adoptive T cell cancer immunotherapy. **2016**, 380, 413-423		81
652	Engineering wonders. **2016**, 124, 763-764		
651	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. **2016**, 8, 1393-1404		7
650	Notable advances 2016. **2016**, 22, 1374-1376		
649	Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. **2016**, 39, 249-59		6
648	Combining in silico evolution and nonlinear dimensionality reduction to redesign responses of signaling networks. **2017**, 13, 066015		1
647	SYNTHETIC BIOLOGY. Customizing cell-cell communication. **2016**, 13, 285		2
646	Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?. **2016**, 4, 269-78		61
645	Mysteries in a Minimal Genome. **2016**, 2, 274-7		9
644	Receptor combinations hone T-cell therapy. **2016**, 34, 389-91		2
643	Cancer: CARs: new models abound. **2016**, 15, 157		1

642	Bioorthogonal Chemical Activation of Kinases in Living Systems. **2016**, 2, 325-31		89
641	Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. **2016**, 18, 1382-1392		5
640	Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. *Cell*, **2016**, 167, 419-432.e16	56.2	335
639	Monitoring cell-cell contacts in vivo in transgenic animals. **2016**, 143, 4073-4084		9
638	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. **2016**, 11, 368-84		50
637	Modular engineering of cellular signaling proteins and networks. **2016**, 39, 106-114		46
636	Pluripotent stem cells as a model for embryonic patterning: From signaling dynamics to spatial organization in a dish. **2016**, 245, 976-90		21
635	Cellular immunotherapy for malignant gliomas. **2016**, 16, 1265-75		30
634	A part toolbox to tune genetic expression in Bacillus subtilis. **2016**, 44, 7495-508		108
633	Gene-modified, cell-based therapies-an overview. **2016**, 18, 1351-1359		4
632	Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. **2016**, 13, 1043-1049		178
631	Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells. **2016**, 6, 30798		36
630	Biology and clinical application of CAR T cells for B cell malignancies. **2016**, 104, 6-17		47
629	Engineering cell-based therapies to interface robustly with host physiology. **2016**, 105, 55-65		12
628	Stem Cells: A Renaissance in Human Biology Research. *Cell*, **2016**, 165, 1572-1585	56.2	67
627	Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. *Cell*, **2016**, 164, 780-91	56.2	440
626	Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response. **2016**, 22, 271-273		10
625	Immunotherapy: Two antigens are better than one. **2016**, 16, 128-9		5

624	A Receptor for All Occasions. *Cell*, **2016**, 164, 599-600	56.2	4
623	Synthetic biology: Sensing with modular receptors. **2017**, 13, 131-132		13
622	Masked Chimeric Antigen Receptor for Tumor-Specific Activation. **2017**, 25, 274-284		49
621	A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. **2017**, 10, 1		144
620	Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. **2017**, 10, 35		63
619	Designed cell consortia as fragrance-programmable analog-to-digital converters. **2017**, 13, 309-316		30
618	Cell-Based Therapeutics: Making a Faustian Pact with Biology. **2017**, 23, 104-115		8
617	New development in CAR-T cell therapy. **2017**, 10, 53		188
616	Molecular Imaging in Synthetic Biology, and Synthetic Biology in Molecular Imaging. **2017**, 19, 373-378		15
615	Creating to understand - developmental biology meets engineering in Paris. **2017**, 144, 733-736		7
614	An oxygen sensitive self-decision making engineered CAR T-cell. **2017**, 7, 39833		102
613	The Principles of Engineering Immune Cells to Treat Cancer. *Cell*, **2017**, 168, 724-740	56.2	583
612	The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. **2017**, 45, 23-35		22
611	CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. **2017**, 23, 430-450		67
610	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. **2017**, 8, 573-589		47
609	Sensing Bad: Are Co-stimulatory CAR-Expressing □T Cells Safer?. **2017**, 25, 1064-1066		1
608	CAR T-cell therapy: Balance of efficacy and safety. **2017**, 51, 237-250		4
607	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. **2017**, 17, 50		6

606	Personalized T cell-mediated cancer immunotherapy: progress and challenges. **2017**, 48, 142-152	68
605	Nongenetic Reprogramming of the Ligand Specificity of Growth Factor Receptors by Bispecific DNA Aptamers. **2017**, 139, 6554-6557	57
604	Modular lentiviral vector system for chimeric antigen receptor design optimization. **2017**, 43, 107-114	3
603	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. **2017**, 8, 896-925	40
602	Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. **2017**, 35, 229-253	74
601	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. **2017**, 8, 861-877	43
600	Adoptive T cell therapy: An overview of obstacles and opportunities. **2017**, 123, 2154-2162	59
599	Mammalian synthetic biology in the age of genome editing and personalized medicine. **2017**, 40, 57-64	12
598	Mammalian Synthetic Biology: Engineering Biological Systems. **2017**, 19, 249-277	36
597	Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. **2017**, 187, 11-21	16
596	Practical considerations for chimeric antigen receptor design and delivery. **2017**, 17, 961-978	9
595	Therapeutic T cell engineering. **2017**, 545, 423-431	420
594	Development of CAR T cells designed to improve antitumor efficacy and safety. **2017**, 178, 83-91	67
593	Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. **2017**, 35, 453-462	144
592	Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. **2017**, 39, 1010428317695949	13
591	Cancer Immunotherapy: Whence and Whither. **2017**, 15, 635-650	24
590	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. **2017**, 178, 31-47	58
589	Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy. **2017**, 1, 447-466	21

588	CAR T-cell therapy of solid tumors. **2017**, 95, 356-363	106
587	Immune targets and neoantigens for cancer immunotherapy and precision medicine. **2017**, 27, 11-37	139
586	Synthetic Biology-The Synthesis of Biology. **2017**, 56, 6396-6419	103
585	Synthetische Biologie die Synthese der Biologie. **2017**, 129, 6494-6519	7
584	Rewiring human cellular input-output using modular extracellular sensors. **2017**, 13, 202-209	91
583	Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. **2017**, 12, 305-330	42
582	The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. **2017**, 177, 13-26	16
581	Synthetic biology Engineering cell-based biomedical devices. **2017**, 4, 50-56	5
580	Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. *Cell*, **2017**, 171, 1138-1150.e15	81
579	Building with intent: technologies and principles for engineering mammalian cell-based therapies to sense and respond. **2017**, 4, 127-133	6
578	Advancing therapeutic applications of synthetic gene circuits. **2017**, 47, 133-141	17
577	Enhancing human regulatory T cells in vitro for cell therapy applications. **2017**, 190, 139-147	3
576	Multiplexing Engineered Receptors for Multiparametric Evaluation of Environmental Ligands. **2017**, 6, 2042-2055	21
575	Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. **2017**, 28, 1047-1060	33
574	Cell-mediated enzyme prodrug cancer therapies. **2017**, 118, 35-51	26
573	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy. **2017**, 9, 837-849	1
572	Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors. **2017**, 20, 2639-2653	44
571	Engineered proteins with sensing and activating modules for automated reprogramming of cellular functions. **2017**, 8, 477	12

570 Reprogramming cellular functions with engineered membrane proteins. **2017**, 47, 92-101 13

569 The what, when and how of CAR T cell therapy for ALL. **2017**, 30, 275-281 13

568 Trial Watch: Adoptively transferred cells for anticancer immunotherapy. **2017**, 6, e1363139 37

567 Notch Signaling in Development, Tissue Homeostasis, and Disease. **2017**, 97, 1235-1294 394

566 Epsin-Dependent Ligand Endocytosis Activates Notch by Force. *Cell*, **2017**, 171, 1383-1396.e12 56.2 55

565 Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway. **2017**, 7, 132-145 8

564 [Adoptive transfer of T lymphocytes]. **2017**, 24, 256-262

563 Chimeric antigen receptor T-cells for B-cell malignancies. **2017**, 187, 59-82 17

562 Engineering CAR-T cells. **2017**, 5, 22 199

561 Synthetic biology-inspired therapies for metabolic diseases. **2017**, 47, 59-66 17

560 Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. **2017**, 23, 3061-3071 89

559 CAR-T therapy for leukemia: progress and challenges. **2017**, 182, 135-144 7

558 Utilization of a fluidic infrastructure for the realization of enzyme-based Boolean logic operations. **2017**, 32, 139-156 8

557 Reprogramming the Transcriptional Response to Hypoxia with a Chromosomally Encoded Cyclic Peptide HIF-1 Inhibitor. **2017**, 6, 518-527 18

556 CAR T-cells for cancer therapy. **2017**, 33, 190-226 21

555 The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. **2017**, 1, 7-7 11

554 CARs on the Highway: Chimeric Antigen Receptor Modified T Cells for the Adoptive Cell Therapy of Malignant Diseases. **2017**, 2

553 CRISPR Genome Engineering for Human Pluripotent Stem Cell Research. **2017**, 7, 4445-4469 18

552	Synthetic Gene Expression Circuits for Designing Precision Tools in Oncology. **2017**, 5, 77	5
551	Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. **2017**, 6,	34
550	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. **2017**, 8, 267	47
549	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. **2017**, 8, 1655	16
548	Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. **2017**, 10, 151	66
547	Driving T-cell immunotherapy to solid tumors. **2018**, 36, 215-219	75
546	Refining cell therapy. **2018**, 359, 1112-1113	4
545	T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. **2018**, 46, 131-146	10
544	Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. **2018**, 11, 22	122
543	Multicomponent Supported Membrane Microarray for Monitoring Spatially Resolved Cellular Signaling Reactions. **2018**, 2, 1800015	7
542	Engineering Axl specific CAR and SynNotch receptor for cancer therapy. **2018**, 8, 3846	22
541	Generalized extracellular molecule sensor platform for programming cellular behavior. **2018**, 14, 723-729	66
540	CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. **2018**, 66, 39-42	31
539	Multigene delivery in mammalian cells: Recent advances and applications. **2018**, 36, 871-879	5
538	Regulation of T cell proliferation with drug-responsive microRNA switches. **2018**, 46, 1541-1552	22
537	Aroma-triggered pain relief. **2018**, 2, 58-59	
536	Current state and future prospects of immunotherapy for glioma. **2018**, 10, 317-339	38
535	Programming gene and engineered-cell therapies with synthetic biology. **2018**, 359,	106

534	Synthetic Biology: Immunotherapy by Design. **2018**, 20, 95-118		21
533	Human c-SRC kinase (CSK) overexpression makes T cells dummy. **2018**, 67, 525-536		6
532	Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. **2018**, 41, 45-52		15
531	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. **2018**, 200, 459-468		109
530	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. **2018**, 131, 2621-2629		96
529	Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. *Cell*, **2018**, 173, 1426-1438.e11	56.2	297
528	Synthetic Biology in Immunotherapy and Stem Cell Therapy Engineering. **2018**, 349-372		0
527	Remote Control of Mammalian Cells with Heat-Triggered Gene Switches and Photothermal Pulse Trains. **2018**, 7, 1167-1173		26
526	Bottom-up approaches in synthetic biology and biomaterials for tissue engineering applications. **2018**, 45, 599-614		12
525	CAR T cell immunotherapy for human cancer. **2018**, 359, 1361-1365		1163
524	Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. **2018**, 9, 867-878		40
523	Synthetic genetic circuits in crop plants. **2018**, 49, 16-22		32
522	Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. **2018**, 39, 167-176		93
521	Cellular Biosensors with Engineered Genetic Circuits. **2018**, 3, 13-26		45
520	Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. **2018**, 59, 2040-2055		9
519	High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. **2018**, 6, 36-46		118
518	Programmable full-adder computations in communicating three-dimensional cell cultures. **2018**, 15, 57-60		42
517	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. **2018**, 142, 1738-1747		31

516	Taking regulatory T-cell therapy one step further. **2018**, 23, 509-515	11
515	D□eloppement des CAR-T dans les tumeurs solides. **2018**, 105 Suppl 2, S178-S187	0
514	CAR-T cells : indications actuelles en p□iatrie et perspectives de d□eloppement. **2018**, 105 Suppl 2, S147-S157	0
513	. **2018**,	7
512	Making CAR T Cells a Solid Option for Solid Tumors. **2018**, 9, 2593	100
511	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. **2018**, 61, 1320-1332	9
510	Generation of regulable EGFRvIII targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma. **2018**, 507, 59-66	4
509	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. **2018**, 8, 513	21
508	Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. **2019**, 12, 193-204	14
507	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. **2018**, 8, 539	23
506	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. **2018**, 11, 142	72
505	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. **2018**, 9, 2740	45
504	Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. **2018**, 18, 1095-1106	3
503	Hierarchical Organization Endows the Kinase Domain with Regulatory Plasticity. **2018**, 7, 371-383.e4	12
502	Self-Adjusting Cytokine Neutralizer Cells as a Closed-Loop Delivery System of Anti-Inflammatory Biologicals. **2018**, 7, 2518-2528	
501	NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. **2018**, 9, 1718	26
500	WITHDRAWN: CAR T cells : indications actuelles en p□iatrie et perspectives de d□eloppement. **2018**,	
499	Two-photon fluorescent polydopamine nanodots for CAR-T cell function verification and tumor cell/tissue detection. **2018**, 6, 6459-6467	12

498	Programmable protein circuits in living cells. **2018**, 361, 1252-1258	138
497	The development of CAR design for tumor CAR-T cell therapy. **2018**, 9, 13991-14004	20
496	Strategies to Address Chimeric Antigen Receptor Tonic Signaling. **2018**, 17, 1795-1815	80
495	Synthetic cytokine receptors transmit biological signals using artificial ligands. **2018**, 9, 2034	19
494	Designer T-cells and T-cell receptors for customized cancer immunotherapies. **2018**, 41, 96-103	2
493	Designing cell function: assembly of synthetic gene circuits for cell biology applications. **2018**, 19, 507-525	111
492	Computer-aided biochemical programming of synthetic microreactors as diagnostic devices. **2018**, 14, e7845	10
491	Chemogenetic control of gene expression and cell signaling with antiviral drugs. **2018**, 15, 519-522	18
490	Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. **2018**, 2018, 2386187	59
489	Seeking Convergence and Cure with New Myeloma Therapies. **2018**, 4, 567-582	5
488	CAR T-cell Integration of Multiple Input Signals Allows for Precise Targeting of Cancer. **2018**, 8, 918-920	2
487	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. **2018**, 9, 1740	108
486	The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. **2018**, 9, 3049	45
485	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. **2018**, 9, 239	26
484	Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. **2018**, 9, 1104	61
483	Versatile CAR T-cells for cancer immunotherapy. **2018**, 22, 73-80	13
482	Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. **2018**, 29, 739-756	22
481	Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy. **2018**, 24, 78-83	6

480	The Molecular Mechanism of Notch Activation. **2018**, 1066, 47-58	17
479	Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation. **2018**, 14, 42-49	36
478	Allogene and Celularity move CAR-T therapy off the shelf. **2018**, 36, 375-377	6
477	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. **2018**, 18, 653-664	17
476	Precise and label-free tumour cell recognition based on a black phosphorus nanoquenching platform. **2018**, 6, 5613-5620	6
475	Driving cars to the clinic for solid tumors. **2018**, 25, 165-175	41
474	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. **2018**, 8, 972-987	66
473	Synthetic gene circuits for the detection, elimination and prevention of disease. **2018**, 2, 399-415	49
472	Programming CAR-T cells to kill cancer. **2018**, 2, 377-391	138
471	A chemically induced proximity system engineered from the plant auxin signaling pathway. **2018**, 9, 5822-5827	4
470	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. **2018**, 13, e0197349	41
469	Caffeine-inducible gene switches controlling experimental diabetes. **2018**, 9, 2318	36
468	Synthetic biology-inspired design of signal-amplifying materials systems. **2019**, 22, 25-34	13
467	Bioelectronic Interface Between Enzyme-Based and DNA-Based Computing Systems. **2019**, 335-355	0
466	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. **2019**, 18, 125	113
465	Notch signaling in breast cancer: From pathway analysis to therapy. **2019**, 461, 123-131	29
464	A long way to the battlefront: CAR T cell therapy against solid cancers. **2019**, 10, 3112-3123	18
463	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. **2019**, 37, 1049-1058	202

462	Application of CAR T cells for the treatment of solid tumors. **2019**, 164, 293-327		7
461	Membrane Organization and Physical Regulation of Lymphocyte Antigen Receptors: A Biophysicist's Perspective. **2019**, 252, 397-412		3
460	Modulation of chimeric antigen receptor surface expression by a small molecule switch. **2019**, 19, 44		39
459	Recent advances in developing and applying biosensors for synthetic biology. **2019**, 3, 042002		6
458	TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. **2019**, 14, e0224015		15
457	Immune-Based Therapies in Acute Leukemia. **2019**, 5, 604-618		18
456	Paving New Roads for CARs. **2019**, 5, 583-592		14
455	An AND-Gated Drug and Photoactivatable Cre- System for Spatiotemporal Control in Cell-Based Therapeutics. **2019**, 8, 2359-2371		11
454	Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform. *Cell*, **2019**, 179, 880-894.e10	56.2	50
453	P116 PERIOSTIN PROMOTES ENDOPLASMIC RETICULUM STRESS-MEDIATED FIBROSIS IN CROHNS DISEASE. **2019**, 25, S57-S57		
452	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. **2019**, 36, 471-482		139
451	Future prospects for CD8 regulatory T cells in immune tolerance. **2019**, 292, 209-224		42
450	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. **2019**, 34, 1780-1788		7
449	Mesothelin as a biomarker for targeted therapy. **2019**, 7, 18		39
448	Clinical lessons learned from the first leg of the CAR T cell journey. **2019**, 25, 1341-1355		200
447	Massively parallel RNA device engineering in mammalian cells with RNA-Seq. **2019**, 10, 4327		20
446	Engineering and Design of Chimeric Antigen Receptors. **2019**, 12, 145-156		149
445	Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors. **2019**, 10, 218		29

444	Mechanisms of Notch signaling: a simple logic deployed in time and space. **2019**, 146,	85
443	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. **2019**, 37, 107411	8
442	Recent perspective on CAR and FcεCR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. **2019**, 166, 335-346	11
441	The making and function of CAR cells. **2019**, 212, 53-69	11
440	Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRP? axis. **2019**, 8, 4245-4253	38
439	Protein-based parts and devices that respond to intracellular and extracellular signals in mammalian cells. **2019**, 52, 47-53	10
438	Gene editing for immune cell therapies. **2019**, 37, 1425-1434	95
437	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. **2019**, 8,	72
436	Redox-Based Synthetic Biology Enables Electrochemical Detection of the Herbicides Dicamba and Roundup via Rewired Escherichia coli. **2019**, 4, 1180-1184	16
435	CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. **2019**, 141, 41-46	16
434	3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. **2019**, 38,	89
433	Novel approaches to promote CAR T-cell function in solid tumors. **2019**, 19, 789-799	3
432	When CAR Meets Stem Cells. **2019**, 20,	4
431	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. **2019**, 20,	140
430	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. **2019**, 35, 489-503.e8	123
429	Engineering advanced cancer therapies with synthetic biology. **2019**, 19, 187-195	28
428	Linear double-stranded DNAs as innovative biological parts to implement genetic circuits in mammalian cells. **2019**, 286, 2341-2354	4
427	The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. **2019**, 40, 292-309	40

426	Therapeutic gene editing in haematological disorders with CRISPR/Cas9. **2019**, 185, 821-835	17
425	Applications of molecular engineering in T-cell-based immunotherapies. **2019**, 11, e1557	4
424	From synthetic biology to human therapy: engineered mammalian cells. **2019**, 58, 108-116	25
423	CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. **2019**, 37, 328-335	22
422	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T´Cell Therapy for Solid Tumors. **2019**, 79, 401-415	13
421	Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. **2019**, 40, 258-272	16
420	Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. **2019**, 9, 69	48
419	Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. **2019**, 20,	31
418	Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies. **2019**, 11,	26
417	Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology. **2019**, 7, 43	31
416	Constructing Synthetic Pathways in Plants: Strategies and Tools. **2019**, 77-113	0
415	NR4A transcription factors limit CAR T cell function in solid tumours. **2019**, 567, 530-534	274
414	On-target restoration of a split T cell-engaging antibody for precision immunotherapy. **2019**, 10, 5387	16
413	CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges. **2019**, 20,	15
412	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. **2019**, 12, 128	52
411	Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells. **2019**, 9, 1448	11
410	CAR T Cells: A Snapshot on the Growing Options to Design a CAR. **2019**, 3, e172	21
409	T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. **2019**, 31, 430-438	6

408	Current status and hurdles for CAR-T cell immune therapy.. **2019**, 1, 148-155		3
407	CAR-T Cells: Future Perspectives. **2019**, 3, e188		22
406	Mechanisms of failure of chimeric antigen receptor T-cell therapy. **2019**, 26, 427-433		18
405	The Current Status of Immunotherapy in Thoracic Malignancies. **2019**, 45-75		
404	Engineering mammalian cells for disease diagnosis and treatment. **2019**, 55, 87-94		16
403	Synthetic Biology: Engineering Mammalian Cells To Control Cell-to-Cell Communication at Will. **2019**, 20, 994-1002		10
402	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. **2019**, 33, 45-60		46
401	Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. **2018**, 9, 3062		37
400	Nanoscale Mechanosensing of Natural Killer Cells is Revealed by Antigen-Functionalized Nanowires. **2019**, 31, e1805954		23
399	Teaching an old dog new tricks: next-generation CAR T cells. **2019**, 120, 26-37		115
398	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. **2019**, 25, 2560-2574		196
397	CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification. *Cell*, **2019**, 176, 254-267.e16	56.2	46
396	Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells. **2019**, 54, 1138-1140		3
395	T-cells "□la CAR-T(e)" - Genetically engineering T-cell response against cancer. **2019**, 141, 23-40		15
394	Gene Therapy for Neoplastic Hematology in Transplant Setting. **2019**, 245-264		
393	Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematology. **2019**, 27-53		
392	Steering CAR T cells to distinguish friend from foe. **2019**, 8, e1271857		13
391	Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. **2020**, 75, 26-32		10

390	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. **2020**, 205, 107419		43
389	Current Immunotherapeutic Strategies in Cancer. **2020**,		4
388	Late Events After CD-19 CAR-T Treatment. **2020**, 26, e1-e2		1
387	Determinants of response and resistance to CAR T cell therapy. **2020**, 65, 80-90		28
386	CART manufacturing process and reasons for academy-pharma collaboration. **2020**, 217, 39-48		4
385	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. **2020**, 17, 147-167		347
384	Mammalian signaling circuits from bacterial parts. **2020**, 16, 110-111		2
383	Challenges and Opportunities to Improve CAR T-Cell Therapy. **2020**, 63-80		1
382	Synthetic biology technologies for beta cell generation. **2020**, 407-420		
381	CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. **2020**, 472, 175-180		83
380	Cell Reprogramming for Immunotherapy. **2020**,		1
379	The future of cellular immunotherapy for childhood leukemia. **2020**, 32, 13-25		6
378	CAR T-Cell Therapy for CNS Malignancies. **2020**, 165-198		
377	CAR 2.0: The Next Generation of Synthetic Receptor‐Based Cellular Therapy for Cancer. **2020**, 199-208		
376	Chimeric Antigen Receptor Therapies. **2020**, 349-359		
375	Synthetic regulation of multicellular systems for regenerative engineering. **2020**, 16, 42-51		1
374	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. *Cell*, **2020**, 183, 126-142.e17	56.2	101
373	Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. **2020**, 11, 215-228.e5		26

372	Intelligent cell-based therapies for cancer and autoimmune disorders. **2020**, 66, 207-216	3
371	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. **2020**, 28, 2320-2339	74
370	When de novo-designed protein logics meet CAR-T therapies. **2020**, 30, 946-947	1
369	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. **2020**, 2020, 4241864	2
368	A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. **2020**, 28, 2564-2576	4
367	Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation. **2020**, 12, 185	19
366	Design of Multipartite Transcription Factors for Multiplexed Logic Genome Integration Control in Mammalian Cells. **2020**, 9, 2964-2970	0
365	Immunotherapy with NK cells: recent developments in gene modification open up new avenues. **2020**, 9, 1777651	13
364	Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. **2020**, 9, e1147	4
363	Engineering Next-Generation CAR-T Cells for Better Toxicity Management. **2020**, 21,	18
362	Adoptive T cell therapy: Boosting the immune system to fight cancer. **2020**, 49, 101437	11
361	Precise T cell recognition programs designed by transcriptionally linking multiple receptors. **2020**, 370, 1099-1104	40
360	Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. **2020**, 18, 428	27
359	The Most Logical Approach to Improve CAR T Cell Therapy. **2020**, 11, 421-423	
358	PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. **2020**, 8, 57	5
357	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. **2020**, 8,	8
356	Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. **2020**, 11, 1280	104
355	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. **2020**, 12,	3

354	CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. **2020**, 158, 17-35	10
353	The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. **2020**, 12,	8
352	Engineering CAR-T Cells for Next-Generation Cancer Therapy. **2020**, 38, 473-488	115
351	Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield. **2020**, 12,	8
350	Thermal Control of Engineered T-cells. **2020**, 9, 1941-1950	13
349	Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. **2020**, 20, 394-408	7
348	Chemical Artificial Internalizing Receptors for Primary T Cells. **2020**, 7, 2001395	3
347	Mechanogenetics for cellular engineering and cancer immunotherapy. **2020**, 66, 88-94	4
346	Improving CAR T-cells: The next generation. **2020**, 57, 115-121	5
345	Regulatory T cell therapy: Current and future design perspectives. **2020**, 356, 104193	16
344	Beyond CAR T cells: Engineered VδVδ T cells to fight solid tumors. **2020**, 298, 117-133	3
343	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. **2020**, 11, 4810	39
342	Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKe complex inhibitor BX795. **2020**, 18, 363	7
341	CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. **2020**, 20, 456	2
340	A minireview on multiparameter-activated nanodevices for cancer imaging and therapy. **2020**, 12, 21571-21582	3
339	CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19HLA-C1 Malignant B Cells While Sparing CD19HLA-C1 Healthy B Cells. **2020**, 12,	7
338	Breaking Bottlenecks for the TCR Therapy of Cancer. **2020**, 9,	14
337	New targets and technologies for CAR-T cells. **2020**, 32, 510-517	7

336	Designed protein logic to target cells with precise combinations of surface antigens. **2020**, 369, 1637-1643	48
335	Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. **2020**, 11, 4166	21
334	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. **2020**, 12,	3
333	Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Genome Editing. **2020**, 9,	0
332	Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction. **2020**, 12,	3
331	A guide to the design of synthetic gene networks in mammalian cells. **2021**, 288, 5265-5288	4
330	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. **2020**, 1-27	6
329	Engineering microrobots for targeted cancer therapies from a medical perspective. **2020**, 11, 5618	89
328	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. **2020**, 34, 2688-2703	23
327	Innovative synthetic signaling technologies for immunotherapy. **2020**, 16, 1-8	0
326	The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. **2020**, 11, 1608	22
325	SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy. **2020**, 92, e12917	2
324	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. **2020**, 8, 19	17
323	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. **2020**, 11, 1128	17
322	Building sophisticated sensors of extracellular cues that enable mammalian cells to work as "doctors" in the body. **2020**, 77, 3567-3581	17
321	Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. **2020**, 16, 262-271	5
320	Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours. **2020**, 12,	19
319	T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. **2020**, 147, 281-295	20

318	Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. **2020**, 11, 326		27
317	Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology. **2020**, 4, 121-139		5
316	Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation. **2020**, 3, 116		9
315	Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. **2020**, 11, 176		37
314	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. **2020**, 12,		45
313	Tumor Microenvironment. **2020**,		1
312	Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. **2020**, 9, 1777064		14
311	Fasten the seat belt: Increasing safety of CAR T-cell therapy. **2020**, 29, 1039-1045		1
310	Cell-cell contact-induced gene editing/activation in mammalian cells using a synNotch-CRISPR/Cas9 system. **2020**, 11, 299-303		7
309	Mechanotransduction in T Cell Development, Differentiation and Function. **2020**, 9,		11
308	Engineering Synthetic Signaling in Plants. **2020**, 71, 767-788		8
307	Engineering light-controllable CAR T cells for cancer immunotherapy. **2020**, 6, eaay9209		44
306	T Cell Engineering and the Rise of CAR-T Cell Therapies. **2020**, 69-90		
305	DNA-Based Reprogramming Strategy of Receptor-Mediated Cellular Behaviors: From Genetic Encoding to Nongenetic Engineering.. **2020**, 3, 2796-2804		11
304	New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. **2020**, 98, 299-327		14
303	The Emerging Landscape of Immune Cell Therapies. *Cell*, **2020**, 181, 46-62	56.2	104
302	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. **2020**, 20, 469-480		5
301	Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma. **2020**, 17, 70-82		5

300	Diverse Anti-Tumor Immune Potential Driven by Individual IFNΣ Subtypes. **2020**, 11, 542	4
299	Multispecific drugs herald a new era of biopharmaceutical innovation. **2020**, 580, 329-338	78
298	A novel chimeric antigen receptor redirecting T-cell specificity towards CD26 cancer cells. **2021**, 35, 119-129	6
297	Cellular immunotherapies for cancer. **2021**, 190, 41-57	16
296	The Evolving Management of Peritoneal Surface Malignancies. **2021**, 58, 100860	0
295	Notch Signaling in Embryology and Cancer. **2021**,	0
294	Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy. **2021**, 42, 45-59	8
293	Engineering precision therapies: lessons and motivations from the clinic. **2021**, 6, ysaa024	1
292	DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. **2021**, 16, 214-223	18
291	Cytotoxic CD8 T cells in cancer and cancer immunotherapy. **2021**, 124, 359-367	101
290	Current Progress in CAR-T Cell Therapy for Hematological Malignancies. **2021**, 12, 326-334	36
289	Synthetic promoters to induce immune-effectors into the tumor microenvironment. **2021**, 4, 143	3
288	pH-responsive antibodies for therapeutic applications. **2021**, 28, 11	2
287	Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. **2021**, 131,	13
286	A T cell redirection platform for co-targeting dual antigens on solid tumors. **2021**, 13, 1933690	
285	T cell circuits that sense antigen density with an ultrasensitive threshold.	0
284	CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. **2021**, 12, 1804-1814	11
283	A modular and controllable T cell therapy platform for acute myeloid leukemia. **2021**, 35, 2243-2257	4

282	Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR Circuits.	1
281	Treatment and resistance of glioblastoma to CAR T-cell immunotherapies. **2021**, 453-471	
280	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. **2021**, 12, 511	23
279	In´vitro T lymphopoiesis. **2021**, 23-53	
278	Cell-Free Characterization of Coherent Feed-Forward Loop-Based Synthetic Genetic Circuits.	
277	Current Advances in Immunotherapy for Glioblastoma. **2021**, 23, 21	9
276	Clinically-driven design of synthetic gene regulatory programs in human cells.	6
275	Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. **2021**, 13,	5
274	Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. **2021**, 206, 669-675	2
273	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. *Cell*, **2021**, 184, 881-898.	19
272	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. **2020**, 11, 569117	5
271	Model-guided design of mammalian genetic programs. **2021**, 7,	11
270	Genetic engineering of T cells for immunotherapy. **2021**, 22, 427-447	17
269	Biosupramolecular Systems: Integrating Cues into Responses. **2021**, 143, 4467-4482	13
268	Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. **2021**, 2, 296-312.e8	7
267	Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. **2021**, 13,	3
266	A multiplexed, automated evolution pipeline enables scalable discovery and characterization of biosensors. **2021**, 12, 1437	9
265	T cell circuits that sense antigen density with an ultrasensitive threshold. **2021**, 371, 1166-1171	25

264	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. **2021**, 62, 2052-2063		3
263	Targeting loss of heterozygosity for cancer-specific immunotherapy. **2021**, 118,		14
262	Anti-CD19 CAR T cells potently redirected to kill solid tumor cells. **2021**, 16, e0247701		3
261	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. **2021**, 44, 495-523		7
260	Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?. **2021**, 2, 100244		0
259	Pharmacologic Control of CAR T Cells. **2021**, 22,		3
258	Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. **2021**, 16, 218-233		0
257	Reactions Related to CAR-T Cell Therapy. **2021**, 12, 663201		6
256	CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. **2021**, 13,		2
255	Hypoxia-sensing CAR T´cells provide safety and efficacy in treating solid tumors. **2021**, 2, 100227		16
254	SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. **2021**, 13,		32
253	Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. **2021**, 17, 643-659		2
252	T Cells as the Future of Cancer Therapy. **2021**, 11, 798-800		0
251	Programmable protein circuit design. *Cell*, **2021**, 184, 2284-2301	56.2	8
250	SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. **2021**, 13,		61
249	Synthetic Artificial Apoptosis-Inducing Receptor for On-Demand Deactivation of Engineered Cells. **2021**, 8, 2004432		0
248	Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic cells.		2
247	Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. **2021**, 12, 687822		7

246	Novel synthetic biology approaches for developmental systems. **2021**, 16, 1051-1064	3
245	The antigen-binding moiety in the driver's seat of CARs. **2022**, 42, 306-342	3
244	Acute Myeloid Leukemia: Is It T Time?. **2021**, 13,	2
243	Biophysics of Notch Signaling. **2021**, 50, 157-189	18
242	JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment. **2021**, 12, 638639	1
241	Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs. **2021**, 14, 101070	2
240	Cell-Free Characterization of Coherent Feed-Forward Loop-Based Synthetic Genetic Circuits. **2021**, 10, 1406-1416	4
239	Strategies to improve the safety profile of CAR-T therapy. **2021**, 8, 48-60	
238	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. **2021**, 6, 100102	7
237	Engineering a Second-Order DNA Logic-Gated Nanorobot to Sense and Release on Live Cell Membranes for Multiplexed Diagnosis and Synergistic Therapy. **2021**, 133, 15950-15954	1
236	Engineering a Second-Order DNA Logic-Gated Nanorobot to Sense and Release on Live Cell Membranes for Multiplexed Diagnosis and Synergistic Therapy. **2021**, 60, 15816-15820	18
235	Recent Advances in Single-Cell Profiling and Multispecific Therapeutics: Paving the Way for a New Era of Precision Medicine Targeting Cardiac Fibroblasts. **2021**, 23, 82	1
234	Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy. **2021**, 19, 175	2
233	Reprogramming signal transduction through a designer receptor tyrosine kinase. **2021**, 4, 752	2
232	Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. **2021**, 9, 1047-1060	1
231	Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. **2021**, 29, 3398-3409	1
230	Theranostic cells: emerging clinical applications of synthetic biology. **2021**, 22, 730-746	13
229	BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. **2021**, 22, 983-995	27

228	Detection in molecular communications with ligand receptors under molecular Interference. **2021**, 103186	2
227	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. **2021**, 19, 154	4
226	Rational design of heterodimeric receptors capable of activating target signaling molecules. **2021**, 11, 16809	
225	Programming Novel Cancer Therapeutics: Design Principles for Chimeric Antigen Receptors. **2021**, 353-375	
224	Control of the activity of CAR-T cells within tumours via focused ultrasound. **2021**, 5, 1336-1347	21
223	Imaging-guided fine tuning of CAR synapse dynamics and T cell triggering.	
222	Gene-circuit therapy on the horizon: synthetic biology tools for engineered therapeutics. **2021**, 68, 377-383	1
221	Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. **2021**, 118,	3
220	Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. **2021**, 5, 1348-1359	13
219	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. **2021**, 69, 471-486	4
218	Engineering Cell-Based Systems for Smart Cancer Therapy. 2100134	2
217	A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety Challenges.	0
216	A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. **2021**, 12, 707211	3
215	Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. **2021**, 23, 820-832	0
214	Synthetic biomarkers: a twenty-first century path to early cancer detection. **2021**, 21, 655-668	8
213	Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells. **2021**, 1	3
212	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. **2021**, 2, 648-665	3
211	Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway. **2021**, 10, 62	0

210	Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. **2021**, 32, 1011-1028	3
209	Advances in engineering and synthetic biology toward improved therapeutic immune cells. **2021**, 20, 100342	1
208	Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. **2021**, 369, 104436	1
207	Design and development of engineered receptors for cell and tissue engineering. **2021**, 28,	1
206	Multi-input biocomputer gene circuits for therapeutic application. **2021**, 28, 100371	1
205	Synthetic receptors for logic gated T cell recognition and function. **2021**, 74, 9-17	1
204	Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. **2021**, 10, e1286	3
203	Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastoma.	2
202	Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. **2021**, 18, 199-214	44
201	Interfacing Enzyme-Based and DNA-Based Computing Systems: From Simple Boolean Logic to Sophisticated Reversible Logic Systems. **2021**, 353-377	0
200	Engineered Tools to Study Intercellular Communication. **2021**, 8, 2002825	10
199	T Cell Reprogramming Against Cancer. **2020**, 2097, 3-44	14
198	Advances and Challenges of CAR T Cells in Clinical Trials. **2020**, 214, 93-128	7
197	Chimeric Antigen Receptors for the Tumour Microenvironment. **2020**, 1263, 117-143	7
196	Chimeric Antigen Receptor (CAR) Redirected T Cells. **2021**, 251-302	1
195	Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy. **2021**, 1287, 201-222	10
194	Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy. **2021**, 23, 1003-1019	8
193	Synthetic receptors to understand and control cellular functions. **2020**, 633, 143-167	5

192	Emerging CAR landscape for cancer immunotherapy. **2020**, 178, 114051	6
191	Cytokine IL-36 improves CAR T-cell functionality and induces endogenous antitumor response. **2021**, 35, 506-521	13
190	Engineering bacteria for cancer therapy. **2019**, 3, 623-629	3
189	Elucidation and refinement of synthetic receptor mechanisms. **2020**, 5, ysaa017	9
188	Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting.	2
187	Acoustogenetic Control of CAR T Cells via Focused Ultrasound.	2
186	Remote control of CAR T cell therapies by thermal targeting.	0
185	Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors.	2
184	Rapid screening of engineered microbial therapies in a 3-D multicellular model.	1
183	DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapies.	4
182	Rapid, Low-Cost Detection of Water Contaminants Using RegulatedIn VitroTranscription.	17
181	Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. **2019**, 4,	10
180	Precision design of stable genetic circuits carried in highly-insulated E.´coli genomic landing pads. **2020**, 16, e9584	17
179	VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells. **2018**, 9, 9021-9029	15
178	Why Immunotherapy Fails in Multiple Myeloma. **2021**, 2, 1-42	1
177	Rewiring MAP kinases in Saccharomyces cerevisiae to regulate novel targets through ubiquitination. **2016**, 5,	7
176	Engineering living therapeutics with synthetic biology. **2021**, 20, 941-960	17
175	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. **2017**, 4, 51-65	1

174	Hierarchical organization endows the kinase domain with regulatory plasticity.	
173	Linear-double-stranded DNA (ldsDNA) based AND logic computation in mammalian cells.	
172	A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation.	
171	Regulating innovation in the early development of cell therapies. **2021**, 1,	0
170	Heterologous expression of methylxanthine synthesis enzymes in mammalian cells and their use as reporter proteins.	
169	CAR-T. **2020**, 633-647	
168	Synthetic Biology-Empowered Hydrogels for Medical Diagnostics. **2021**, 178, 197-226	0
167	Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.	
166	Elucidation and refinement of synthetic receptor mechanisms.	
165	Thermal Control of T-cell Immunotherapy.	
164	Implementing Logic Gates for Safer Immunotherapy of Cancer. **2021**, 12, 780399	2
163	Synergistic effects of low-dose chemotherapy and T cells in renal cell carcinoma. **2020**, 44, 897-908	1
162	Model-guided design of mammalian genetic programs.	0
161	Editor's Pick: Tumour-Associated Hypoxia: Can We Give Chimeric Antigen Receptor T Cells More Breathing Space?.	
160	Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy. **2017**, 2, 100-113	1
159	Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. **2019**, 9, 1889-1904	22
158	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. **2021**, 9,	0
157	Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report. **2021**,	1

156	Genetically Modified Cellular Therapies for Malignant Gliomas. **2021**, 22,	1
155	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. **2021**, 22,	1
154	Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations. **2022**, 61-101	
153	Synthetic Gene Circuits: Design, Implement, and Apply. **2021**, 1-18	
152	Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. **2021**, 10,	3
151	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.. **2022**, 14,	3
150	[Perspectives for the evolution and use of CAR-T cells].. **2021**, 108, S18-S27	
149	The evolution of synthetic receptor systems.. **2022**,	6
148	Synthetic gene circuits for higher-order information processing. **2022**, 373-395	0
147	Biology of CAR-T Cells. **2022**, 29-55	
146	Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.. **2022**,	1
145	Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.. **2022**, 1535370222107429	
144	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.. **2022**, 14,	3
143	TCR-T Immunotherapy: The Challenges and Solutions.. **2021**, 11, 794183	5
142	Current state and next-generation CAR-T cells in multiple myeloma.. **2022**, 54, 100929	7
141	Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers.. **2022**, 14,	2
140	Engineering CAR T cells for enhanced efficacy and safety.. **2022**, 6, 011502	0
139	New horizons in the identification of circulating tumor cells (CTCs): An emerging paradigm shift in cytosensors.. **2022**, 203, 114043	1

138	Preclinical testing of CAR T cells in zebrafish xenografts.. **2022**, 167, 133-147	
137	Light-Controllable Binary Switch Activation of CAR T Cells.. **2022**,	0
136	Synthetic Biology-based Optimization of T cell Immunotherapies for Cancer. **2022**, 22, 100372	
135	Better by design: What to expect from novel CAR-engineered cell therapies?. **2022**, 107917	1
134	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. **2021**, 9, e002755	0
133	Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer.. **2021**, 9, 778020	1
132	Remote Control of Mammalian Therapeutic Designer Cells. **2021**, 53-67	
131	Immunotherapy-based cancer vaccines. **2022**, 397-412	
130	Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.	
129	Emerging CAR T Cell Strategies for the Treatment of AML.. **2022**, 14,	0
128	Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. 20210106	7
127	Overcoming Barriers to Widespread Use of CAR-Treg Therapy in Organ Transplant Recipients.. **2022** ,	
126	Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.. **2022**, 12, 832765	2
125	CAR-T cell therapy for lung cancer: Potential and perspective.. **2022**,	5
124	Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.. **2021**,	0
123	Principles for the design of multicellular engineered living systems.. **2022**, 6, 010903	0
122	Notch signaling pathway: architecture, disease, and therapeutics.. **2022**, 7, 95	11
121	Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.. **2022**, 13, 822004	1

120	To go or not to go? Biological logic gating engineered T cells.. **2022**, 10,		0
119	DNA Input Classification by a Riboregulator-Based Cell-Free Perceptron.. **2022**,		1
118	CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.. **2022**,		1
117	Hurdles to breakthrough in CAR T cell therapy of solid tumors.. **2022**, 13, 140		5
116	Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.. **2022**, 1877, 188701		1
115	Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.. **2021**, 79, 14		3
114	Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens.		0
113	CAR-NK Cells: From Natural Basis to Design for Kill.. **2021**, 12, 707542		2
112	The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets.. **2021**, 2, 1406-1422		5
111	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics.. **2021**, 23,		1
110	Modular design of synthetic receptors for programmed gene regulation in cell therapies.. *Cell*, **2022**, 185, 1431-1443.e16	56.2	5
109	Next-Generation CAR T-cell Therapies.. **2022**, OF1-OF14		1
108	Development of CAR T Cell Therapy in Children-A Comprehensive Overview.. **2022**, 11,		1
107	The tricks for fighting against cancer using CAR NK cells: A review.. **2022**, 101817		0
106	Image_1.JPEG. **2020**,		
105	Image_2.jpeg. **2020**,		
104	Image_3.JPEG. **2020**,		
103	Image_4.JPEG. **2020**,		

102	Image_5.JPEG. **2020**,	
101	Image_6.JPEG. **2020**,	
100	Data_Sheet_1.pdf. **2019**,	
99	Image_1.TIF. **2018**,	
98	Image_2.TIF. **2018**,	
97	Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.. **2022**, 183, 255-274	
96	Development of Cancer Immunotherapies.. **2022**, 183, 1-48	0
95	Programming Receptor Clustering with DNA Probabilistic Circuits for Enhanced Natural Killer Cell Recognition.. **2022**, e202203800	1
94	Programming Receptor Clustering with DNA Probabilistic Circuits for Enhanced´Natural Killer Cell´Recognition.	
93	SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.. **2022**,	
92	Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells.. **2022**, 11, 27	0
91	A Genetically Encodable and Chemically Disruptable System for Synthetic Post-Translational Modification Dependent Signaling.	0
90	Engineering the next generation of cell-based therapeutics.	4
89	CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges. 2101262	
88	Current and future perspectives of chimeric antigen receptors against glioblastoma.	
87	Next Generation Natural Killer Cells for Cancer Immunotherapy. **2022**, 13,	0
86	Designer protein circuits enable safe cancer immunotherapy.	
85	Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. **2022**, 10, 1493	2

84	Synthetic immunotherapy: programming immune cells with novel and sophisticated logic capabilities. **2022**,	0
83	Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity.	1
82	Emerging Biomaterials Imaging Antitumor Immune Response. 2204034	1
81	Programmable Mixed-Signal Biocomputers in Mammalian Cells.	
80	Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism. **2022**, 13, 193-216	1
79	Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. **2022**, 156, 155920	0
78	Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions. **2022**, 240, 108231	1
77	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. **2022**, 14, 3230	0
76	Smart Programmable Scalable Dual-Mode Diagnostic Logic Nanoflare Strategy for Dual-Tumor Marker Detection. **2022**, 94, 9715-9723	0
75	Biointerface Engineering with Nucleic Acid Materials for Biosensing Applications. 2201069	2
74	Highly Multiplexed Selection of RNA Aptamers Against a Small Molecule Library.	
73	Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. 13,	
72	Multiple-Aptamer-Integrated DNA-Origami-Based Chemical Nose Sensors for Accurate Identification of Cancer Cells. **2022**, 94, 10192-10197	1
71	Latest developments in the pathobiology of Ewing sarcoma. **2022**, 35, 100440	
70	Logic-gated antibody pairs that selectively act on cells co-expressing two antigens.	0
69	The Regulatory Effects of MicroRNAs on Tumor Immunity. **2022**, 2022, 1-12	1
68	Precision cancer targeting with antibody pairs.	
67	Secretory co-factors in next-generation cellular therapies for cancer. 13,	

66	Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus. **2022**,	
65	Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.	0
64	Production of CD87 Antigen-Specific CAR-T Lymphocytes and Assessment of Their In Vitro Functional Activity. **2022**, 15, 340-348	0
63	CAR-T cell potency: from structural elements to vector backbone components. **2022**, 10,	0
62	Automated, scaled, transposon-based production of CAR T cells. **2022**, 10, e005189	0
61	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. 13,	1
60	Rethinking cancer targeting strategies in the era of smart cell therapeutics.	1
59	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.	1
58	High-performance multiplex drug-gated CAR circuits. **2022**,	1
57	Highly multiplexed selection of RNA aptamers against a small molecule library. **2022**, 17, e0273381	0
56	Chimeric antigen receptor engineered cells and their clinical application in infectious disease. **2022**, 2,	0
55	Sowing the seeds for advanced synthetic plant biology.	0
54	Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies. **2022**, 309, 121016	0
53	Novel technologies for improving the safety and efficacy of CAR-T cell therapy.	0
52	Chimeric antigen receptor T cells applied to solid tumors. 13,	0
51	Emerging technologies for genetic control systems in cellular therapies. **2022**, 78, 102833	0
50	Activation-inducible CAR expression enables precise control over engineered CAR T cell function.	0
49	Let turn the CAR-T cells ON and OFF precisely. **2022**, 40, 1264-1266	0

48	Recent progress of gene circuit designs in immune cell therapies. **2022**, 13, 864-873	0
47	Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers. **2022**,	0
46	Nano-Biohybrid DNA Engager That Reprograms the T-Cell Receptor. **2022**, 144, 22458-22469	0
45	The application of mechanobiotechnology for immuno-engineering and cancer immunotherapy. 10,	0
44	Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. **2023**, 20, 49-62	1
43	The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions. **2022**, 14, 6173	1
42	Multidimensional control of therapeutic human cell function with synthetic gene circuits. **2022**, 378, 1227-1234	4
41	Synthetic cytokine circuits that drive T cells into immune-excluded tumors. **2022**, 378,	3
40	CAR T-cell therapies in China: rapid evolution and a bright future. **2022**, 9, e930-e941	0
39	CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy Against Cancer. **2023**, 15, 117	0
38	Genetically edited T-cell membrane coated AIEgen nanoparticles effectively prevents glioblastoma recurrence. **2022**, 121981	1
37	Monitoring of cell-cell communication and contact history in mammals. **2022**, 378,	0
36	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. **2022**, 56, 409-419	0
35	High-throughput functional characterization of combinations of transcriptional activators and repressors.	0
34	Modifying enzyme replacement therapy □A perspective.	0
33	Adherens junctions organize size-selective proteolytic hotspots critical for Notch signalling. **2022**, 24, 1739-1753	0
32	A Multiscale Protein Abundance Structured Population Kinetic Model Systematically Explores the Design Space of Constitutive and Inducible CAR-T cells.	0
31	Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.	0

30	DNA-Templated Anchoring of Proteins for Programmable Cell Functionalization and Immunological Response. **2023**, 23, 183-191	0
29	CAR T cells: engineered immune cells to treat brain cancers and beyond. **2023**, 22,	0
28	CAR-T: What Is Next?. **2023**, 15, 663	1
27	Engineering a Scalable and Orthogonal Platform for Synthetic Communication in Mammalian Cells.	0
26	Instructional materials that control cellular activity through synthetic Notch receptors. **2023**, 297, 122099	0
25	Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells. **2023**, 32, 322-339	0
24	Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy. **2023**, 316, 121409	0
23	Bioinspired microrobots: Opportunities and challenges in targeted cancer therapy. **2023**, 354, 439-452	0
22	Anti-ROR1 CAR-T cells: Architecture and performance. 10,	0
21	Challenges of Anti-Mesothelin CAR-T-Cell Therapy. **2023**, 15, 1357	0
20	CAR immune cells: design principles, resistance and the next generation. **2023**, 614, 635-648	0
19	Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs.	0
18	Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive Tumors. **2023**, 13, 459	0
17	CD19 CAR antigen engagement mechanisms and affinity tuning. **2023**, 8,	0
16	Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. 14,	1
15	Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors. **2023**,	0
14	ErbB- and MUC1-targetted CAR-T cell immunotherapy of oral squamous cell carcinoma. 4,	0
13	Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. **2023**, 21,	0

12	Design and Mathematical Analysis of Activating Amplifiers that Enable Modular Temporal Control in Synthetic Circuits.	0
11	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. 14,	0
10	Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors. **2023**, 4, 1-16	0
9	Comprehensive Overview of CAR-T Cell Therapy, Engineering Process and Future Prospects. 36, 376-384	0
8	A recombinant adenovirus vector containing the synNotch receptor gene for the treatment of triple-negative breast cancer. 13,	0
7	Cell surface proteomics reveal a strategy for targeting myeloma through combinatorial targeting of TNFRSF8 and TMPRSS11E.	0
6	A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy. **2023**, 14,	0
5	A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.	0
4	Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.	0
3	MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors. **2023**, 27, 241-256	0
2	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. **2023**, 173-192	0
1	T cell development and function.	0